Bupropion Bupropion is uniquely positioned among antidepressants because it tends to be weight-neutral or promote mild weight loss
REWIND trial (Gerstein HC et al., Lancet 2019) Safety Considerations When Using Both Medications Whilst the combination of Basaglar and Trulicity is generally well-tolerated, several safety considerations require attention to minimise risks and optimise outcomes
-Lixisenatide is short-acting and might have limited CNS exposure, especially at standard doses
Through its modulation of the NNMT-SAM-NAD+ axis, it enhances energy expenditure and supports more efficient utilization of fat stores for energy, making it a strong candidate in studies exploring metabolic optimization and obesity control
Do not use as a substitute for evaluation of persistent pain, swelling, gastrointestinal bleeding, or suspected tendon rupture
Found the secret to flipping the script